Bristol Myers Squibb is teaming up with Prothena in a high-stakes lab dance to tackle Alzheimer’s disease with two ...

Prothena announced that the Company has initiated an approximate 63% reduction in its workforce.

Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Chardan slashed the firm’s price target on Prothena Corporation plc (NASDAQ:PRTA) on May 27, lowering it to $18 from $40 while maintaining a Buy rating on the shares. Although the firm is ...

Fintel reports that on May 28, 2025, B of A Securities downgraded their outlook for Prothena (NasdaqGS:PRTA) from Neutral to Underperform. Analyst Price Forecast Suggests 1,045.01% Upside As of ...

Prothena’s management has responded by planning significant cost-cutting measures and exploring options to enhance shareholder value. Despite these setbacks, the company remains focused on its ...

Oppenheimer downgraded Prothena Corporation plc (NASDAQ:PRTA) to Perform from Outperform on May 27 without a price target. This rating update came after Prothena Corporation’s (NASDAQ ...